Qure.ai has completed a $65 million Series D funding round, led by Lightspeed and 360 ONE Asset, with participation from Merck Global Health Innovation Fund, Kae Capital, Novo Holdings, Health Quad, and TeamFund.
The funding will accelerate Qure.ai’s expansion into the U.S. and other markets, enhance its investment in AI models, and support strategic acquisitions in the med-tech sector.
Co-Founder and CEO Prashant Warier shared that Qure.ai has become a trusted AI partner for medical imaging in hospitals and healthcare organizations worldwide, addressing healthcare challenges such as imaging backlogs, screening gaps, and resource shortages. He added that the Series D round is an exciting step forward in the company’s mission to reach a billion patients through our solutions.
Founded in 2016, Qure.ai provides AI-driven solutions that enhance healthcare accessibility. With deployments in over 90 countries, the company focuses on critical disease identification, including TB, lung cancer, and stroke. Their AI tools are cleared by the U.S. FDA for 18 indications and certified under EU MDR regulations.
Lightspeed Partner Dev Khare praised Qure.ai as a leader in AI healthcare diagnostics, saying that its AI tools rival the accuracy of radiologists, making quality care more accessible globally. 360 ONE Asset Fund Manager Tarun Sharma highlighted Qure.ai’s impact in real-time TB detection and early diagnosis of lung cancer as transformative for patient care.
Qure.ai leverages deep learning to enhance radiology accuracy through AI-powered analysis of X-rays, CT scans, and ultrasounds, offering faster diagnosis and improved health outcomes for overburdened medical imaging professionals.
